Original Article

Toxicity of Nicotine by Repeated Intratracheal Instillation to F344 Rats

Masanao Yokohira1, Yuko Nakano1, Nozomi Hashimoto1, Keiko Yamakawa1, Fumiko Ninomiya1, Sosuke Kishi1, Kousuke Saoo1,2, and Katsumi Imaida1*

1 Onco-Pathology, Department of Pathology and Host-Defense, Kagawa University, Kagawa 761-0793, Japan
2 Diagnostic Pathology, Kaisei General Hospital, Kagawa 762-0007, Japan

Abstract: In vivo, nicotine in cigarette smoke induces various effects not only on the respiratory system but also the central and peripheral nerve systems, circulatory organs and digestive organs, and there is a possibility of promotion of lung tumorigenesis. The present experiment was conducted to examine histopathological changes caused by nicotine in the lung with repeated intratracheal instillation (i.t.). Six-week-old male F344 rats were administered nicotine by i.t. at doses of 0.05, 0.1 and 0.2 mg nicotine/rat every 3 weeks beginning at week 4, for up to a total of 9 times and were then sacrificed at week 30. The total number of administrations, total dose of nicotine and effective number of rats were 9 times, 0.45 mg and 5 rats and 4 times, 0.20 mg and 5 rats for the 0.05 mg nicotine/rat group; 3 times, 0.30 mg and 5 rats and 4 times, 0.40 mg and 3 rats for the 0.1 mg group; and 3 times, 0.60 mg and 3 rats for the 0.2 mg group, respectively. As a control group, 5 rats were administered 0.2 ml saline/rat 9 times. Some rats administered 0.1 and 0.2 mg nicotine suffered convulsions just after administration. Histopathologically, though proliferative changes were not observed, neutrophil infiltration, edema and fibrosis in the lung were induced by nicotine. In conclusion, repeated treatment of nicotine promoted neurologic symptoms in the acute phase, and strong inflammation in the lungs in the chronic phase, even at a low dose. Toxicity of nicotine is suggested to depend not on total dose of nicotine in the experiment but rather on repeated injury with consecutive administration. (DOI: 10.1293/tox.25.257; J Toxicol Pathol 2012; 25: 257–263)

Key words: nicotine, lung, intratracheal instillation, toxicity, rat

Introduction

There are many chemicals including carcinogens in cigarette smoke, and at least 4000 component compounds have been described1. Of the smoking-related chemicals, nicotine is one of the major important components with toxicity. Nicotine is taken into the blood via the lungs from the inhaled smoke and binds to nicotinic acetylcholine receptors on the central and peripheral nerves2. It thereby induces various effects not only in the respiratory system but also circulatory and digestive organs3-5. In addition, according to a previous report, nicotine enhances proliferation, migration, and radiosensitivity of human malignant glioma cells through EGFR activation6. Nicotine is the addictive component of tobacco acting on neuronal nicotinic receptors (nAChRs). Functional nAChRs are also present on endothelial, hematological and epithelial cells7. Nicotine has been shown to stimulate the growth of solid tumors in vivo and to promote gastric cancer in the stomach8. Tobacco carcinogens can initiate and promote tumorigenesis, so concomitant exposure to nicotine could confer a proliferative advantage to early tumors, although there is no evidence that nicotine itself provokes cancer9.

However, there have only been few reports of in vivo toxicity and histopathological changes on aspiration of nicotine in the respiratory organs. To examine any lung toxicity induced by nicotine, it is necessary to have a system for frequent respiratory exposure. We have previously described a rat in vivo bioassay for detection of hazards due to fine particles by intratracheal instillation (i.t.)10, which can be used for risk assessment of inhaled chemicals. The i.t. method has been proposed as the most reliable route for assessing the pulmonary toxicity of particles in rodents11, although there are biologically different responses to inhalation and instillation12,13. Using this i.t. technique, the present experiment was conducted to histopathologically examine toxicity and cell proliferation caused by nicotine in the lungs by repeated i.t. administration in vivo.
Materials and Methods

**Chemicals**
Nicotine (chemical formula: C₁₀H₁₄N₂ and CAS: 54-11-5) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and suspended in saline (Otsuka isotonic sodium chloride solution, Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan).

**Animals**
Male Fischer-344/DuCrIcrj rats (4 weeks of age) purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan) were maintained in the Division of Animal Experiments, Life Science Research Center, Kagawa University, according to the Institutional Regulations for Animal Experiments. The regulations included the best considerations for animal welfare and good practice of animal handling contributing to the replacement, refinement and reduction of animal testing (3Rs). The protocols of the experiments were approved by the Animal Care and Use Committee for Kagawa University. The animals were housed in polycarbonate cages with white wood chips for bedding and given free access to drinking water and a basal diet, CE-2 (CLEA Japan, Inc., Tokyo, Japan), under controlled conditions of humidity (60 ± 10%), lighting (12-h light/dark cycle) and temperature (24 ± 2°C). The experiments were started after a 2-week acclimation period.

**Experimental design and tissue preparation**
A total of thirty 6-week-old male F344 rats were randomly separated into 6 groups of 5 rats each and scheduled to be administered nicotine by i.t. every 3 weeks from week 4 to 28, for a total of 9 times, and to be sacrificed at week 30. The doses of nicotine were decided to be 0.05, 0.1 and 0.2 mg nicotine/0.2 ml saline/rat based on the report that 0.2 mg nicotine/rat corresponds to a lethal dose for human adults (30–60 mg, 0.5–1.0 mg/kg body weight)⁴¹⁻⁵. The pHs of the diluted nicotine solutions (0.05, 0.1 and 0.2 mg nicotine/0.2 ml saline) were 9.22, 9.42 and 9.60, respectively (pH meter F-52, HORIBA, Ltd., Kyoto, Japan). During the experiment, the third or fourth administrations were not given to the high-dose group, 0.1 and 0.2 mg nicotine/rat, because of the death of some rats following nicotine administration. The final experiment protocol was therefore modified as shown in Table 1. The total numbers of administrations and effective numbers of rats were 9 times and 5 rats (Group 3) and 4 times and 5 rats (Group 2) for the 0.05 mg nicotine/rat group; 3 times and 5 rats (Group 4) and 4 times and 3 rats (Group 5) for the 0.1 mg group; and 3 times and 3 rats (Group 6) for the 0.2 mg group, respectively. As a control group (Group 1), 5 rats were administered 0.2 ml saline/rat 9 times. Total doses of nicotine per rat were 0.00 mg (Group 1), 0.20 (Group 2), 0.45 (Group 3), 0.30 (Group 4), 0.40 (Group 5) and 0.60 (Group 6).

At autopsy, the lungs, liver and kidneys were removed. The lungs were weighed including the trachea and heart first, rinsed in 10% neutral buffered formalin after excision and then infused with 10% neutral buffered formalin. The weights of the lungs were calculated by subtraction of the weight of the remaining trachea and heart. The liver and kidneys were weighed and immersed in 10% neutral buffered formalin for 3 days. Slices of organs were routinely processed for embedding in paraffin for histopathological examination of H&E-stained sections. For lungs, this was routinely performed for 2 slices of the left lobe and 1 slice each of the other lobes. Each lung lobe was examined histopathologically for neutrophil infiltration, pulmonary edema, pulmonary fibrosis, macrophage infiltration in the alveoli, restructuring of walls, granuloma⁴⁶ and atelectasis. Severity for each parameter, except for atelectasis, was divided as follows: 0, no change; 1, weak; 2, moderate; and 3, severe. Severity for atelectasis was divided as follows: 0, none; 1, 1 lobe; 2, 2 lobes; and 3, more than 3 lobes.

**Statistical analysis**
Body and organ weights were analyzed by the Tukey-Kramer post hoc test. P values less than 0.05 were considered significant.

**Results**
All rats in Groups 4, 5, and 6 (0.1 or 0.2 mg nicotine/rat) laid on their backs and suffered convulsions a few seconds after each i.t. administration. This symptom continued for approximately 5 to 10 seconds. At the third or fourth administration, there were a number of mortalities, although other rats survived the acute symptoms. As noted above, due to the deaths, the experimental design was modified, and the number of administrations was modified in some groups. Final body and organ weights are summarized in Table 2. The body weights of the rats in Group 3 (0.05 mg nicotine/...
9 times) showed significant decreases compared with Group 1 (control group). Absolute and relative weights of the lung were significantly increased in Groups 2, 3 and 5 compared with Group 1 (control group). Regarding liver weights, there were no significant differences compared with Group 1 (saline control group).

Histopathologically, the lungs of Groups 2–6 (nicotine-treated groups) showed inflammatory changes, neutrophil infiltration, pulmonary edema, pulmonary fibrosis, macrophage infiltration in the alveoli, restructuring of walls and granuloma, in all animals (incidence: 100%) (Table 3). Atellectasis was observed in Groups 2, 3, 5 and 6. No proliferative alteration of alveolar cells was apparent. The lungs of Group 3 (0.05 mg nicotine 9 times) showed the severest and most widespread inflammatory changes in all rats (Fig. 1-E and F). The inflammation in Groups 2, 4, 5 and 6 persisted until autopsy (week 30), despite the 17–20-week period between the final instillation of nicotine and autopsy. The areas of inflammation in the lungs of Groups 2, 4, 5 and 6 were localized and showed clear borders with normal areas (Fig. 1-C, Fig. 2-A, C, E).

All rats (Group 1–6) also showed severe lymphoid cell infiltration around the bronchus in their lungs with almost the same degree. The saline control group (Group 1) also featured severe lymphoid cell infiltration around the bronchus, but not inflammatory changes in the alveoli (Fig. 1-A, B).

In the kidneys and livers of animals treated with nicotine (Groups 2–6), no remarkable changes were observed macroscopically and histopathologically compared with the control group (Group 1).

**Discussion**

In the present study, rats treated with 0.1 or 0.2 mg nicotine suffered convulsions after each i.t. administration. The behavioral effects of nicotine are reported to be attributed to an action on nicotinic receptors, their over stimulation of nicotinic receptors in the brain resulting in clonic-tonic convulsions. Damaj MI et al. reported that nicotine enhances the release of glutamate either directly or indirectly (membrane depolarization that opens L-type calcium channels) and that glutamate release in turn stimulates N-methyl-D-aspartate receptors, thus triggering a cascade of events leading to nitric oxide formation and possibly seizure. Nicotine at a dose of 0.75 or 1.0 mg/kg body weight is reported to lead to a decrease in cortical after-discharge duration and influence seizure susceptibility, but not cause any detectable neuronal damage.

The body weights of the rats treated with nicotine tended to be decreased compared with the control group (Group 1). Furthermore, in Group 3 (0.05 mg nicotine 9 times), the decrease was significant as compared with Group 1 (control group). This decrease in body weight can be considered due to the toxicity of nicotine. The total dose of nicotine in Group 3 was 0.45 mg and was lower than that in Group 6 (0.60 mg). However, the number of administrations in Group 3 was 9, and this was the maximum number. The results suggest that the decrease in body weight depends not only on the total dose of nicotine in the experiment but also on repeated and consecutive administrations. The lung weights of the rats treated with nicotine were increased significantly compared with the control group (Group 1) but not in the group treated with 0.1 mg nicotine 3 times (Group 4). This result corre-

### Table 2. Body and Organ Weights of the Rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>Nicotine/ rat (mg)</th>
<th>Total number of i.t.</th>
<th>No. of rats</th>
<th>Body weight (g)</th>
<th>Liver Absolute (g)</th>
<th>Liver Relative (%)</th>
<th>Lung Absolute (g)</th>
<th>Lung Relative (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.00 (saline)</td>
<td>9</td>
<td>5</td>
<td>341.6 ± 10.6 e</td>
<td>9.7 ± 0.5</td>
<td>2.8 ± 0.1</td>
<td>2.0 ± 0.2</td>
<td>0.6 ± 0.1</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>4</td>
<td>5</td>
<td>314.6 ± 21.7</td>
<td>8.8 ± 0.5</td>
<td>2.8 ± 0.2</td>
<td>2.7 ± 0.2</td>
<td>0.9 ± 0.1</td>
</tr>
<tr>
<td>3</td>
<td>0.05</td>
<td>9</td>
<td>5</td>
<td>304.3 ± 24.5 b</td>
<td>8.9 ± 0.6</td>
<td>2.9 ± 0.1</td>
<td>2.8 ± 0.4 c</td>
<td>0.9 ± 0.2 c</td>
</tr>
<tr>
<td>4</td>
<td>0.10</td>
<td>3</td>
<td>5</td>
<td>328.9 ± 13.0</td>
<td>8.6 ± 0.4</td>
<td>2.6 ± 0.1</td>
<td>1.6 ± 0.4</td>
<td>0.5 ± 0.1</td>
</tr>
<tr>
<td>5</td>
<td>0.10</td>
<td>4</td>
<td>5</td>
<td>335.7 ± 5.7</td>
<td>9.9 ± 0.8 c</td>
<td>2.9 ± 0.3 b</td>
<td>2.9 ± 0.3 b c</td>
<td>0.9 ± 0.1 b c</td>
</tr>
<tr>
<td>6</td>
<td>0.20</td>
<td>3</td>
<td>3</td>
<td>312.1 ± 7.9</td>
<td>8.8 ± 0.2</td>
<td>2.8 ± 0.0</td>
<td>2.6 ± 0.4 b</td>
<td>0.8 ± 0.1 b</td>
</tr>
</tbody>
</table>

a Average ± standard deviation. b P<0.05 vs. Group 1. c P<0.05 vs. Group 4.

### Table 3. Scoring Indices of Histopathological Changes

<table>
<thead>
<tr>
<th>Groups</th>
<th>Nicotine/ rat (mg)</th>
<th>Total number of i.t.</th>
<th>No. of rats</th>
<th>Neutrophil infiltration</th>
<th>Pulmonary edema</th>
<th>Pulmonary fibrosis</th>
<th>Macrophage infiltration in the alveoli</th>
<th>Restructuring of the walls of the alveoli</th>
<th>Granuloma</th>
<th>Atellectasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.00 (saline)</td>
<td>9</td>
<td>5</td>
<td>1.0 ± 0.4 e</td>
<td>0.0 ± 0.0</td>
<td>0.0 ± 0.0</td>
<td>1.0 ± 0.0</td>
<td>2.0 ± 0.0</td>
<td>1.0 ± 0.0</td>
<td>0.0 ± 0.0</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>4</td>
<td>5</td>
<td>2.4 ± 0.5</td>
<td>1.0 ± 0.0</td>
<td>1.2 ± 0.4</td>
<td>2.0 ± 0.0</td>
<td>1.4 ± 0.5</td>
<td>2.2 ± 0.5</td>
<td>1.6 ± 0.9</td>
</tr>
<tr>
<td>3</td>
<td>0.05</td>
<td>9</td>
<td>5</td>
<td>2.8 ± 0.4</td>
<td>1.6 ± 0.5</td>
<td>1.4 ± 0.5</td>
<td>2.2 ± 0.4</td>
<td>1.0 ± 0.0</td>
<td>2.8 ± 0.5</td>
<td>0.6 ± 0.9</td>
</tr>
<tr>
<td>4</td>
<td>0.10</td>
<td>3</td>
<td>5</td>
<td>2.4 ± 0.5</td>
<td>1.0 ± 0.0</td>
<td>1.0 ± 0.0</td>
<td>1.8 ± 0.4</td>
<td>1.0 ± 0.0</td>
<td>2.4 ± 0.0</td>
<td>0.0 ± 0.0</td>
</tr>
<tr>
<td>5</td>
<td>0.10</td>
<td>4</td>
<td>3</td>
<td>2.7 ± 0.6</td>
<td>1.7 ± 0.6</td>
<td>1.3 ± 0.6</td>
<td>1.7 ± 0.6</td>
<td>1.7 ± 0.6</td>
<td>2.7 ± 0.6</td>
<td>2.3 ± 0.6</td>
</tr>
<tr>
<td>6</td>
<td>0.20</td>
<td>3</td>
<td>3</td>
<td>2.3 ± 1.2</td>
<td>1.3 ± 0.6</td>
<td>1.3 ± 0.6</td>
<td>1.7 ± 0.6</td>
<td>1.3 ± 0.6</td>
<td>2.0 ± 0.6</td>
<td>2.0 ± 1.0</td>
</tr>
</tbody>
</table>

a Average ± standard deviation.
Toxicity of Nicotine

Fig. 1. Histopathological findings for lungs in Groups 1–3. The lungs of Group 3 (0.05 mg nicotine 9 times) showed the severest inflammatory changes in all rats (E and F). Inflammation in Group 2 (0.05 mg 4 times) persisted until autopsy (week 30). The saline control group (Group 1) also demonstrated severe lymphoid cell infiltration around the bronchus, as in the other groups (Group 2–6) (A and B). A, saline control ×9 (Group 1) (magnification: ×20); B, saline control ×9 (Group 1) (×200); C, 0.05 mg nicotine ×4 (group 2) (×12.5); D, 0.05 mg nicotine ×4 (group 2) (×100); E, 0.05 mg nicotine ×9 (group 3) (×12.5); F, 0.05 mg nicotine ×9 (group 3) (×40).

Corresponds with inflammatory changes caused by nicotine in the lungs, excluding the decrease in lung weight in Group 4.

Histopathologically, the lungs of Group 3 (0.05 mg nicotine 9 times, 0.45 mg total dose) showed the severest and most widespread inflammatory changes in all rats. Histopathological inflammation also did not solely depend on the total dose of nicotine in the experiment, and repeated and consecutive administrations correspond with a de-
crease in body weight. Mabley et al. reported that intra-peritoneal injection of 0.2 or 0.4 mg/kg nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury induced by intratracheal lipopolysaccharide (LPS, 50 µl). The difference in the result of their report, exerting an anti-inflammation effect, and our experiment, inducing an inflammatory change, is suggested to be due to the difference in administration route. In the present experiment, the

Fig. 2. Histopathological findings for lungs in Groups 4–6. Inflammation in Groups 4, 5 and 6 persisted until autopsy (week 30) with severe lymphoid cell infiltration around the bronchus (A–F). A, 0.10 mg nicotine ×3 (Group 4) (magnification: ×12.5); B, 0.10 mg nicotine ×3 (Group 4) (×100); C, 0.10 mg nicotine ×4 (Group 5) (×20); D, 0.10 mg nicotine ×4 (Group 5) (×100); E, 0.20 mg nicotine ×3 (Group 6) (×12.5); F, 0.20 mg nicotine ×3 (group 6) (×100).
pHs of the diluted nicotine solutions (0.05, 0.1 and 0.2 mg nicotine/0.2 ml saline) were very alkaline at 9.22, 9.42 and 9.60, respectively (saline: 6.14). Alkaline compounds cause liquefaction necrosis, which in turn causes ongoing invasion into deeper layers of tissue. This is the same problem that occurs with accidental drinking of lye solution, the high pH of which is associated with esophageal ulceration. Vancula EM et al. concluded that the critical pH that causes esophageal ulceration is 12.5. Thus, it is more difficult to conclude that lung inflammatory changes were due to the nicotine itself or the high pH.

All rats (Groups 1–6) showed almost the same degree of severe lymphoid cell infiltration around the bronchi in their lungs, not only those treated with nicotine but also those treated with saline vehicle alone. Our previous 30-week experiment using F344 male rats also showed severe lymphoid cell infiltration around the trachea in a saline control group with 100% incidence, and this finding was reported as large granular lymphocytic lymphoma (LGL lymphoma)23. In this context, it should be mentioned that F344 rats demonstrate an incidence of over 50% of LGL lymphoid cell neoplasms in F344 rat should not be grouped with nonlymphoid neoplasms in determining the toxicity and carcinogenicity of test substances24.

CYP2A5 is reported to be involved in metabolism of nicotine and its major circulating metabolite, cotinine, in the mouse liver25. CYP2A5, a mouse cytochrome P450 monoxygenase that shows high similarities to human CYP2A6 and CYP2A13 in protein sequence and substrate specificity, is expressed in multiple tissues, including the liver, kidney, lung and nasal mucosa. In humans, CYP2A6 is the predominant enzyme responsible for 70–80% of nicotine metabolism to cotinine26,27. The much higher exposure to cotinine than to nicotine in smokers should be taken into consideration, since cotinine suppression of apoptosis may play an important role in lung tumorigenesis in vivo28. We have established a bioassay using the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) as an initiating carcinogen29. In the lungs of A/J female mice, the initial event in this model is reported to be formation of O2-methylguanine-DNA, a major promutagenic adduct that leads to GC→AT transitional mispairing and subsequent activation of the K-ras proto-oncogene30,31. We have previously reported inhibitory effects of 8-methoxypsoralen, a potent human CYP2A6 inhibitor, on NNK-induced lung carcinogenesis in female A/J mice32,33. Human CYP2A6 (mouse CYP2A5) might affect the metabolism of both nicotine and NNK. Therefore, it is strongly expected that human CYP2A6 inhibitors would have major effects on lung carcinogenesis after administration of nicotine and NNK.

In conclusion, repeated i.t. treatment with nicotine in the present study was associated with neurologic symptoms (convulsions) in the acute phase, and marked inflammation in the lungs in the chronic phase, even at a low dose. Toxicity of nicotine is suggested to depend not on total dose of nicotine in the experiment but rather repeated and consecutive exposure.

Acknowledgments: We thank Dr. Malcolm A. Moore for critical reading of the manuscript and Sanae Kushida for assistance in its preparation.

References

2. Hone AJ, Meyer EL, McIntyre M, and McIntosh JM. Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the alpha6beta4* subtype. FASEB J. 26: 917–926. 2012. [Medline] [CrossRef]
31. Ronai ZA, Gradia S, Peterson LA, and Hecht SS. G to A transitions and G to T transversions in codon 12 of the K-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis. 14: 2419–2422. 1993. [Medline] [CrossRef]  